PharmacoEconomics

, Volume 26, Issue 9, pp 769–779 | Cite as

Valuing Health States for Use in Cost-Effectiveness Analysis

Briefing Paper

Abstract

This article reviews the general issues in valuing health states for use in cost-effectiveness analysis and the specific issues considered by the National Institute for Health and Clinical Excellence (NICE) in its recent review of the methods of technology appraisal. The general issues are how to describe health, how to value health and who should provide the values for health. The specific issues considered by NICE included whether and what should be the reference-case instrument, what to do when there are no data using the reference-case measure, what to do when the reference-case measure is not suitable and how to judge when it is not suitable, how to review and synthesize data, and how to incorporate health-state utility values into cost-effectiveness models.

References

  1. 1.
    Torrance GW. Measurement of health state utilities for economic appraisal: a review. J Health Econ 1986; 5: 1–30PubMedCrossRefGoogle Scholar
  2. 2.
    Brooks R, EuroQol Group. EuroQol: the current state of play. Health Policy 1996; 37: 53–72PubMedCrossRefGoogle Scholar
  3. 3.
    Dolan P. Modeling valuations for EuroQol health states. Med Care 1997; 35: 1095–1108PubMedCrossRefGoogle Scholar
  4. 4.
    Brazier J, Roberts J, Deverill M. The estimation of a preference-based single index measure for health from the SF-36. J Health Econ 2002; 21 (2): 271–292PubMedCrossRefGoogle Scholar
  5. 5.
    Feeny DH, Furlong WJ, Torrance GW, et al. Multiattribute and single-attribute utility function: the Health Utility Index Mark 3 system. Medical Care 2002; 40 (2): 113–128PubMedCrossRefGoogle Scholar
  6. 6.
    Dolan P. The measurement of health related quality of life for use in resource allocation in health care. In: Culyer AJ, Newhouse JP, editors. Handbook of health economics. Vol. 1. Amsterdam: Elsevier Science, 2000Google Scholar
  7. 7.
    International Society for Pharmacoeconomics and Outcomes Research. Pharmacoeconomic guidelines around the world. Lawrenceville (NJ): ISPOR [online]. Available from URL: http://www.ispor.org/peguidelines/index.asp [Accessed 2008 Jul 1]Google Scholar
  8. 8.
    HM Treasury. The green book: appraisal and evaluation in central government. London: TSO, 2004Google Scholar
  9. 9.
    Beattie J, Covey J, Dolan P, et al. On the contingent valuation of safety and the safety of contingent valuation: part 1-caveat investigator. J Risk Uncertainty 1998; 17: 5–25CrossRefGoogle Scholar
  10. 10.
    Olsen JA, Smith RD. Theory versus practice: a review of ‘willingness to pay’ in health and health care. Health Econ 2001; 10: 39–52PubMedCrossRefGoogle Scholar
  11. 11.
    Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. Oxford: Oxford University Press, 1996Google Scholar
  12. 12.
    Donaldson C, Shackley P. Does ‘process utility’ exist? A case study of willingness to pay for laporoscopic cholecystectomy. Soc Sci Med 1997; 44 (5): 285–294CrossRefGoogle Scholar
  13. 13.
    Revicki DA, Leidy NK, Brennan-Diemer F, et al. Integrating patients’ preferences into health outcomes assessment: the multi-attribute asthma symptom utility index. Chest 1998; 114 (4): 998–1007PubMedCrossRefGoogle Scholar
  14. 14.
    Brazier JE, Czoski-Murray C, Roberts J, et al. Estimation of a preference-based index from a condition specific measure: the King’s Health Questionnaire. Med Decis Making 2008; 28 (1): 113–126PubMedCrossRefGoogle Scholar
  15. 15.
    Yang Y, Brazier JE, Tsuchyia A, et al. Estimating a preference-based index from the Over Active Bladder questionnaire. Value Health. In PressGoogle Scholar
  16. 16.
    Hall J, Gerard K, Salkeld G, et al. A cost utility analysis of mammography screening in Australia. Soc Sci Med 1992; 34 (9): 993–1004PubMedCrossRefGoogle Scholar
  17. 17.
    Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford: Oxford University Press, 2005Google Scholar
  18. 18.
    Gafni A, Birch S, Mehrez A. Economics, health and health economics: HYEs versus QALYs. J Health Econ 1993; 12 (3): 325–339PubMedCrossRefGoogle Scholar
  19. 19.
    Richardson J. Cost-utility analysis: what should be measured. Soc Sci Med 1994; 39: 7–21PubMedCrossRefGoogle Scholar
  20. 20.
    Bleichrodt H. A new explanation for the difference between time trade off utilities and standard gamble utilities. Health Econ 2002; 11 (5): 447–456PubMedCrossRefGoogle Scholar
  21. 21.
    Salomon JA. Reconsidering the use of rankings in the valuation of health states: a model for estimating cardinal values from ordinal data. Popul Health Metr 2003; 1 (1): 12 [online]. Available from URL: http://www.pophealthmetrics.com/con tent/1/1/12 [Accessed 2008 Jul 1]PubMedCrossRefGoogle Scholar
  22. 22.
    McCabe C, Brazier J, Gilks P, et al. Using rank data to estimate health state utility models. J Health Econ 2006; 25 (3): 418–431PubMedCrossRefGoogle Scholar
  23. 23.
    Nord E. The person-trade-off approach to valuing health care programs. Med Decis Making 1995; 15: 201–208PubMedCrossRefGoogle Scholar
  24. 24.
    Dolan P, Sutton M. Mapping visual analogue scores onto time trade-off and standard gamble utilities. Soc Sci Med 1997; 44: 1519–1530PubMedCrossRefGoogle Scholar
  25. 25.
    Stevens KJ, McCabe CJ, Brazier JE. Mapping between visual analogue and standard gamble data: results from the UK Health Utilities Index 2 valuation. Health Econ 2006; 15 (5): 527–534PubMedCrossRefGoogle Scholar
  26. 26.
    Ubel PA, Loewenstein G, Jepson C. Whose quality of life? A commentary exploring discrepancies between health state evaluations of patients and the general public. Qual Life Res 2003; 12: 599–607PubMedCrossRefGoogle Scholar
  27. 27.
    Dolan P, Kahneman D. Interpretations of utility and their implications for the valuation of health. Economic Journal 2008; 118: 215–234CrossRefGoogle Scholar
  28. 28.
    Dolan P, Olsen JA. Distributing health care: economic and ethical issues. Oxford: Oxford Medical Publications, 2002Google Scholar
  29. 29.
    National Institute for Health and Clinical Excellence. Social value judgements: principles for the development of NICE guidance [2nd edition: draft for public consultation]. London: NICE, 2007Google Scholar
  30. 30.
    Fitzpatrick R, Bowling A, Gibbons E, et al. A structured review of PROMs in relation to selected chronic conditions, perceptions of quality of care and carer impact. Oxford: National Centre for Health Outcomes Development, 2006Google Scholar
  31. 31.
    Marra CA, Woolcott JC, Kopec JA, et al. A comparison of generic, indirect utility measures (the HUI2, HUB, SF-6D and the EQ-5D) and disease-specific instruments (the RAQoL and the HAQ) in rheumatoid arthritis. Soc Sci Med 2005; 60 (7): 1571–1582PubMedCrossRefGoogle Scholar
  32. 32.
    National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. London: NICE 2004Google Scholar
  33. 33.
    National Institute for Health and Clinical Excellence. Review of the guide to the methods of technology appraisal. London: NICE, 2008 [online]. Available from URL: http://www.nice-.org.uk/aboutnice/howwework/devnicetech/technologyap-praisalprocessguides/guidetothemethodsoftechnologyappraisal jsp [Accessed 2008 Jul 1]Google Scholar
  34. 34.
    McCabe C, Stevens K, Roberts J, et al. Health state values from the HUI-2 descriptive system: results from a UK survey. Health Econ 2005; 14 (3): 231–244PubMedCrossRefGoogle Scholar
  35. 35.
    Brazier JE, Ratcliffe J, Tsuchiya A, et al. Measuring and valuing health for economic evaluation. Oxford: Oxford University Press, 2007Google Scholar
  36. 36.
    Torrance GW, Feeny DH, Furlong WJ, et al. Multiattribute utlity function for a comprehensive health status classification system: Health Utility Index mark 2. Med Care 1996; 34 (7): 702–722PubMedCrossRefGoogle Scholar
  37. 37.
    Stevens K. Working with children to develop dimensions for a preference based generic paediatric health related quality of life measure [08/04 HEDS discussion paper series]. Sheffield: University of Sheffield, 2008Google Scholar
  38. 38.
    US Food and Drug Administration. Center for Drug Evaluation and Research, US Department of Health and Human Services. Guidance for industry: patient-reported outcome measures. Use in medical product development to support labeling claims. Rockville (MD): US EDA, 2006 [online]. Available from URL: http://www.fda.gov/cder/guidance/5460dft.htm [Accessed 2008 Jul 1]Google Scholar
  39. 39.
    Coast J. Reprocessing data to form QALYs. BMJ 1992; 305: 87–90PubMedCrossRefGoogle Scholar
  40. 40.
    Brazier J, Yang Y, Tsuchiya A. Review of methods for mapping between condition specific measures onto generic measures of health: report prepared for the Office of Health Economics. London: OHE, 2007Google Scholar
  41. 41.
    Claxton C. Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics 2008; 26 (9): 781–798PubMedCrossRefGoogle Scholar
  42. 42.
    Ara R, Brazier J. Deriving an algorithm to convert the eight mean SF-36 dimension scores into a mean EQ-5D preference-based score from published studies (where patient level data are not available). Value Health. Epub 2008 May 16Google Scholar
  43. 43.
    Sugar CA, Sturm R, Lee TT, et al. Empirically defined health states for depression from the SF-12. Health Serv Res 1998; (33): 911–928PubMedGoogle Scholar
  44. 44.
    Barton GR, Bankart J, Davis AC, et al. Comparing utility scores before and after hearing-aid provision. Appl Health Econ Health Policy 2004; 3: (2): 103–105PubMedCrossRefGoogle Scholar
  45. 45.
    Espallargues M, Czoski-Murray C, Bansback N, et al. The impact of age related macular degeneration on health state utility values. Invest Ophthalmol Vis Sci 2005; 46: 4016–4023PubMedCrossRefGoogle Scholar
  46. 46.
    Tengs TO, Wallace A. One thousand health-related quality-of-life estimates. Med Care 2000; 38 (6): 583–637PubMedCrossRefGoogle Scholar
  47. 47.
    Stevenson MD, Brazier JE, Calvert NW, et al. Description of an individual patient methodology for calculating the cost-effectiveness of treatments for osteoporosis in women. J Oper Res Soc 2005; 56: 214–221CrossRefGoogle Scholar
  48. 48.
    Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the Dl valuation model. Med Care 2005; 43: 203–220PubMedCrossRefGoogle Scholar
  49. 49.
    Karnon J, Brennan A, Pandor A, et al. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK. Curr Med Res Opin 2005; 21 (1): 91–112CrossRefGoogle Scholar
  50. 50.
    Kaltenthaler E, Shackley P, Stevens K, et al. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess 2002; 6 (22): 1–89PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Health Economics and Decision Science and NICE Decision Support UnitSchool of Health and Related Research, University of SheffieldSheffieldUK

Personalised recommendations